Therefore, UCP inhibition has been proposed as a therapeutic strategy [31], underscoring the need to evaluate UCP levels and activity in breast cancer cells, particularly in those with enhanced proton leak and no increase in total ROS, like the ER+ cells. This evidence concerns the gene UCP1 and breast cancer.